Subsite specificity of anthrax lethal factor and its implications for inhibitor development

Biochemical and Biophysical Research Communications

Volumn 407, Issue 2, 2011, Pages 400-405

  Li, Feng ^a,b,c   Terzyan, Simon ^a   Tang, Jordan ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Bacillus anthracis; Inhibitor; Lethal factor; Specificity

Indexed keywords

AMINO ACID; LEUCINE; METALLOPROTEINASE; METHIONINE; PROLINE; TRYPTOPHAN; TYROSINE;

ARTICLE; BACILLUS ANTHRACIS; CYTOSOL; HYDROLYSIS; HYDROPHOBICITY; LETHAL GENE; LETHALITY; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; DRUG DESIGN; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 79953699014     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.033     Document Type: Article

References (20)

1. Mock M., Fouet A. Anthrax. Annu. Rev. Microbiol. 2001, 55:647-671.
2. Shoop W.L., Xiong Y., Wiltsie J., Woods A., Guo J., Pivnichny J.V., Felcetto T., Michael B.F., Bansal A., Cummings R.T., Cunningham B.R., Friedlander A.M., Douglas C.M., Patel S.B., Wisniewski D., Scapin G., Salowe S.P., Zaller D.M., Chapman K.T., Scolnick E.M., Schmatz D.M., Bartizal K., MacCoss M., Hermes J.D. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. USA 2005, 102:7958-7963.
3. Ascenzi P., Visca P., Ippolito G., Spallarossa A., Bolognesi M., Montecucco C. Anthrax toxin: a tripartite lethal combination. FEBS Lett. 2002, 531:384-388.
4. Bardwell A.J., Abdollahi M., Bardwell L. Anthrax lethal factor-cleavage products of MAPK kinases exhibit reduced binding to their cognate MAPKs. Biochem. J. 2004, 378:569-577.
5. Xiong Y., Wiltsic J., Woods A., Guo J., Pivnichny J.V., Tang W., Bansal A., Cummings R.T., Cunningham B.R., Friedlander A.M., Douglas C.M., Salowe S.P., Zaller D.M., Scolnick E.M., Schmatz D.M., Bartizal K., Hermes J.D., MacCoss M., Chapman K.T. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg. Med. Chem. Lett. 2006, 16:964-968.
6. Tanoue T., Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signalling 2003, 15:455-462.
7. Rainey G.J., Young J.A. Antiotoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. 2004, 2:721-726.
8. Ho D.T., Bardwell A.J., Grewal S., Lverson C., Bardwell L. Interacting JNK-docking sites in MKK7 promotes binding and activation of JNK MAP kinases. J. Biol. Chem. 2006, 281:13169-13179.
9. Turk B.E. Manipulation of host signaling pathway by anthrax toxins. Biochem. J. 2007, 402:405-417.
10. Paniffer A.D., Wong T.Y., Schwarzenbacher R., Renatus M., Petosa C., Blenkowska J. Crystal structure of the anthrax lethal factor. Nature 2001, 414:229-233.
11. Tonello F., Ascendzi P., Montecucco C. The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited. J. Biol. Chem. 2003, 278:40075-40078.
12. Turk B.E., Wong T.Y., Schwarzenbacher R., Jarrell E.T., Leppla S.H., Collier R.J., Liddington R.C., Cantley L.C. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 2004, 11:60-66.
13. Turk B.E. Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Current pharmaceutical biotechnology 2008, 9:24-33.
14. Turner R.T., Koelsch G., Hong L., Castanheira P., Ermolieff J., Ghosh A.K., Tang J. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 2001, 40:10001-10006.
15. Ermolieff J., Loy J.A., Koelsch G., Tang J. Proteolytic activation of recombinant pro-memapsin 2 (pro-β-secretase) studied with new fluorogenic substrate. Biochemistry 2000, 39:12450-12456.
16. Turner R.T., Lin H., Koelsch G., Ghosh A.K., Tang J. Structure locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). Biochemistry 2005, 44:105-112.
17. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Cryst. 1998, D54:905-921.
18. Turner R.T., Loy J.A., Nguyen C., Devasamudram T., Ghosh A.K., Koelsch G., Tang J. Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity. Biochemistry 2002, 27:8742-8746.
19. Li X., Bo H., Zhang X.C., Hartsuck J.A., Tang J. Predicting memapsin (beta-secretase) hydrolytic activity. Protein Sci. 2010, 11:2175-2185.
20. Tonello F., Seveso M., Marin O., Mock M., Montecucco C. Screening inhibitors of anthrax lethal factor. Nature 2002, 418:386.